摘要
小细胞肺癌(SCLC)是一种具有高度侵袭性和致死性的神经内分泌肿瘤。过去十余年,SCLC的治疗没有取得任何突破性的进展。尽管其对放化疗高度敏感,但初始治疗后极易复发,且再次化疗效果欠佳,预后极差。研究认为恶性肿瘤的发生、发展和转移均需要新生血管的参与,这也是抗血管生成类药物治疗恶性肿瘤的理论基础。目前抗血管生成类药物的研究主要集中在血管内皮生长因子(VEGF)信号通路,其代表药物贝伐珠单抗已在非小细胞肺癌、结直肠癌等部分实体瘤中取得成功。然而,大部分抗血管生成类药物在SCLC的治疗中没有获得满意的疗效。全文收集国内外近期相关研究和临床试验报道,对SCLC抗血管生成治疗的现状和进展作简要综述。
Small cell lung cancer（SCLC） is a highly aggressive and lethal neuroendocrine malignancy with little progression during the past decades. Despite high initial response rates to systemic radiochemotherapy,the disease relapses easily and further treatment contains poor therapeutic effects. Malignant tumors need new angiogenesis during their occurrence,development and metastasis. Currently,the exploration of anti-angiogenesis therapy is primarily concentrated on the drugs that target the vascular endothelial growth factor（VEGF） signal pathway. And bevacizumab which is the representative drug of VEGF have shown remarkable prospect in NSCLC and colorectal cancer. However,most results from clinical trials in SCLC have been disappointing. This review is conducted by collecting the recent researches and clinical trials to summarize the current progression of research on anti-angiogenesis therapy in SCLC.
出处
《肿瘤学杂志》
CAS
2017年第9期749-753,共5页
Journal of Chinese Oncology
